PRP vs PRF: Tubes, Protocols & Clinical Applications Compared
Mariana RuizPartager
Reading time: ~10 minutes | Target audience: Dermatologists, plastic surgeons, aesthetic injectors, regenerative medicine clinicians
Last updated: Nov 12, 2026
Introduction
Platelet concentrates have evolved significantly since the initial clinical adoption of first-generation Platelet-Rich Plasma (PRP). The development of second-generation autologous biomaterials—predominantly Platelet-Rich Fibrin (PRF) and its liquid derivatives (injectable PRF / i-PRF)—has expanded clinical options for aesthetic medicine, facial rejuvenation, and hair restoration.
While both modalities leverage autologous platelets and concentrated growth factors (PDGF, TGF-β, VEGF, EGF, IGF-1), they differ fundamentally in tube chemistry, centrifugation dynamics, biological architecture, and growth factor release kinetics. Understanding these biological and technical distinctions is essential for clinicians selecting the optimal autologous preparation for specific anatomical indications.
1. Biological Fundamentals: Liquid Plasma vs. Fibrin Matrix
1.1 Platelet-Rich Plasma (PRP)
PRP relies on an anticoagulant (most commonly Acid Citrate Dextrose Solution A / ACD-A or sodium heparin) present in the collection tube prior to blood draw. The anticoagulant reversibly binds or depletes ionized calcium, preventing the initiation of the clotting cascade during blood collection and centrifugation.
The resulting preparation is an anticoagulated, fluid plasma fraction containing concentrated platelets. Upon injection into tissue (or upon exogenous activation with calcium chloride/thrombin), platelets activate, degranulate, and release the bulk of their stored alpha-granule growth factors in a relatively rapid burst—typically releasing approximately 70–90% of their total growth factor payload within the first 1–2 hours.
1.2 Platelet-Rich Fibrin (PRF)
PRF represents a 100% natural, additive-free autologous preparation. Blood is collected into tubes containing no anticoagulant, no gel separator, and no exogenous additives.
Because no anticoagulant is present, the coagulation cascade begins immediately upon contact with the tube interior. Centrifugation must be initiated rapidly (typically within 60–90 seconds of blood draw) at lower centrifugal forces (the "low-speed centrifugation concept" or LSCC). This allows platelets and leukocytes to become entrapped within a developing three-dimensional fibrin polymer meshwork.
Rather than a rapid growth factor dump, this dense fibrin network acts as a sustained-release bioscaffold, gradually releasing growth factors over a sustained period of 10 to 14 days as the fibrin mesh naturally degrades.
2. Tube Specifications & Materials: PRP vs. PRF
2.1 Tube Wall Material and Surface Chemistry
The contact activation of Factor XII (Hageman factor) initiates the intrinsic coagulation pathway. The interior surface properties of the collection tube are critical to successful PRF formation:
- PRP Tubes: Typically utilize medical-grade PET or specialized glass containing ACD-A or heparin and a thixotropic gel separator. The anticoagulant immediately halts coagulation, allowing flexible centrifugation protocols and longer bench stability.
- PRF Tubes: Manufactured from specialized medical-grade PET engineered to provide a controlled, standardized hydrophobic surface. This controlled surface maintains the delicate balance between allowing enough clotting to form a rich fibrin mesh without triggering premature clumping that would impede centrifugation.
2.2 Gel Separators vs. Additive-Free Separation
PRP collection tubes frequently feature a thixotropic gel separator that forms a physical barrier isolating red blood cells from the plasma layer. Conversely, PRF tubes contain no gel separator; cell separation relies purely on differential density sedimentation under low-speed centrifugal forces.
3. Centrifugation Protocols & Forces
| Parameter | Standard PRP Protocol | Liquid PRF (i-PRF) Protocol | Solid PRF (A-PRF / Leukocyte-PRF) |
|---|---|---|---|
| Tube Type | ACD-A + Gel Separator | Medical-grade PET, Additive-Free | Medical-grade PET, Additive-Free |
| Anticoagulant | ACD-A (or Sodium Heparin) | None (100% autologous) | None (100% autologous) |
| RCF (Gravitational Force) | High (~800–1,500 × g) | Low (~60–200 × g) | Moderate (~200–400 × g) |
| Centrifugation Time | 5–10 minutes | 3–5 minutes | 8–14 minutes |
| Final State | Stable liquid suspension | Liquid (converts to gel post-injection) | Solid fibrin clot / membrane / plug |
| Working Window | ~30–60 minutes | ~10–15 minutes before gelation | Immediate use or press into membrane |
4. Growth Factor Kinetics: Burst vs. Sustained Release
The primary biological differentiator between PRP and PRF lies in the release curve of regenerative signaling molecules:
PRP: Immediate High-Peak Delivery
- Kinetics: Rapid surge. Over 70% of growth factors are released within the first hour of platelet activation.
- Clinical Advantage: Rapid local stimulation of existing fibroblasts, endothelial cells, and stem cells. Highly effective for acute cellular recruitment and combining with mechanical therapies such as microneedling.
PRF: Sustained Physiological Delivery
- Kinetics: Prolonged release. Platelets and leukocytes remain trapped in the fibrin mesh, continuously secreting growth factors over 10 to 14 days as endogenous tissue plasminogen activator (tPA) and cellular enzymes break down the scaffold.
- Clinical Advantage: Sustained tissue presence without artificial cross-linkers. Ideal for structural tissue regeneration, under-eye hollows, and deep dermis biostimulation.
5. Clinical Selection Matrix
When to Select PRP:
- Full-Face Microneedling: PRP’s stable liquid state provides ideal slip, smooth skin gliding, and uniform penetration across micro-channels without risk of needle clogging.
- Large-Volume Surface Coverage: Facial plus neck or décolletage rejuvenation where 4–6ml of liquid volume is required.
- High-Speed Clinic Workflow: Stable working window (up to 45–60 minutes) accommodates multi-step clinical treatments without immediate rushing.
- Combined Formulations: Compatibility with hyaluronic acid (HA) or biotin additives integrated within the tube.
When to Select PRF (Liquid / i-PRF):
- Under-Eye (Tear Trough) Injections: The thin periorbital tissue benefits from PRF's gentle, slow-release profile, minimal post-procedure swelling, and absence of chemical anticoagulants that could exacerbate vascular bruising.
- Hair Follicle Restoration: Prolonged localized growth factor residence around the follicular bulge supports prolonged anagen phase maintenance.
- Targeted Facial Biostimulation: Intradermal injection for stubborn fine lines, nasolabial folds, and perioral rhytids where a temporary natural fibrin scaffold adds subtle volumization.
- Strict Additive-Free Protocols: Patients seeking 100% natural, synthetic-free autologous treatments.
6. Quality Standards and Handling Protocols
Both PRP and PRF procedures require stringent quality management:
- Quality Standards: Collection tubes must be manufactured under ISO 13485-aligned quality management systems and conform to CE medical device standards.
- PRF Timing Discipline: For PRF preparation, the blood draw must be seamless, and centrifugation must start immediately to avoid premature clotting in the syringe or tube before centrifugal layer separation.
- Needle Sizing: Liquid PRF should be delivered with 27G–30G needles or 25G–27G blunt cannulas within 10–12 minutes of preparation before fibrin polymerization increases viscosity.
Frequently Asked Questions
Can PRF replace PRP in all aesthetic procedures?
No. They serve complementary rather than mutually exclusive clinical roles. PRP remains the standard choice for topical glide and delivery during microneedling, large-surface aesthetic treatments, and protocols requiring long working times. PRF is preferred for targeted intradermal injections, tear troughs, and sustained-release indications.
Why are PRF tubes made of medical-grade PET instead of standard glass?
While early dental PRF protocols utilized glass tubes, medical-grade PET tubes engineered with specialized hydrophobic surface properties provide controlled clot formation kinetics without the microscopic silica or chemical activator coatings commonly found on standard diagnostic glass tubes.
Can PRF be mixed with hyaluronic acid?
Liquid PRF can be gently blended with non-crosslinked hyaluronic acid or autologous albumin gel immediately prior to injection to create hybrid biostimulatory gels, provided the mixture is delivered before fibrin mesh consolidation.
Disclaimer: This technical guide is intended for clinical reference by licensed medical practitioners and does not constitute medical advice. Treatment selection should be guided by clinical assessment, product instructions for use, and institutional protocols.
Related reading: PRP tube selection guide and PRF tube guide.
For CE-marked, ISO 13485-manufactured PRP and PRF collection tubes designed for standardized clinical outcomes, explore the VivaPRP product catalog or contact our clinical support team.